ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 107 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $23,140,000 | -68.0% | 501,509 | -41.8% | 0.46% | -16.8% |
Q4 2021 | $72,384,000 | +32.7% | 861,088 | -18.0% | 0.56% | -4.6% |
Q4 2020 | $54,537,000 | +58.9% | 1,050,003 | 0.0% | 0.58% | +16.8% |
Q3 2020 | $34,325,000 | -25.0% | 1,050,003 | 0.0% | 0.50% | -32.5% |
Q2 2020 | $45,783,000 | – | 1,050,003 | – | 0.74% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |